When will Intellia Therapeutics submit a BLA for Lonvo-z?

On Kalshi, the lonvo-z BLA submission market is priced as a binary contract reflecting the probability of submission by Apr 1, 2027. On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. Traders buy or sell shares at prices between 0 and 100 cents, with the current top outcome reflecting 81.0% implied probability. Pricing incorporates milestones such as Phase 3 trial completion, safety data readouts, and regulatory pre-submission meetings. As new clinical or regulatory developments emerge, the contract price adjusts to reflect updated trader expectations about submission timing, with volume and liquidity supporting real-time price discovery.

The market resolves on Apr 1, 2027. Resolution is determined by whether Intellia Therapeutics officially submits a BLA for lonvo-z to the FDA on or before that deadline. The outcome hinges on the company's clinical trial progress, manufacturing readiness, and regulatory strategy. Key catalysts include Phase 3 trial data announcements, FDA feedback from pre-BLA meetings, and company earnings calls or press releases confirming submission timing. Traders monitor these signals to adjust positions ahead of the resolution date.

Several catalysts could shift market odds for lonvo-z BLA submission. Positive Phase 3 efficacy or safety data would likely increase submission probability, while adverse events or trial delays would reduce it. FDA feedback from pre-BLA meetings or Type B meetings could clarify regulatory expectations and timelines. Company earnings calls, investor presentations, or press releases announcing manufacturing scale-up or submission plans would move prices sharply. Competitive approvals in transthyretin amyloidosis or changes in FDA guidance on gene therapy could also influence trader expectations about Intellia's submission readiness and urgency.